A Phase 3, Randomized, Double-blind Study Of Pf-05280586 Versus Rituximab For The First-line Treatment Of Patients With Cd20-positive, Low Tumor Burden, Follicular Lymphoma
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2018
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms REFLECTIONS
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 23 May 2018 Status changed from active, no longer recruiting to completed.
- 26 Jan 2018 Status changed from recruiting to active, no longer recruiting.